Empowerment program

Comprehensive Molecular Tumor Analysis powered by MGI

Comprehensive Molecular Tumor Analysis by ALACRiS

ALACRiS Theranostics has been founded to develop innovative concepts and sustainable solutions for revolutionizing healthcare, biomarker discovery and drug development, with an initial focus on molecular oncology and precision medicine.Our flagship solution is the Comprehensive Molecular Tumor Analysis (CMTA), which is a certified ISO DIN EN 15189:2014 NGS-based innovative tumor diagnostic tool. CMTA integrates genomic and transcriptomic profiling to offer one of the most comprehensive precision oncology tests on the market today. The CMTA is a tumor-agnostic test, also suitable for refractory and rare cancers, as well as cancers of unknown origin (CUPs).

Our technologies are already being used within clinics and have fostered a number of research projects in partnership with academia as well as biotechnology and pharmaceutical companies.

We are delighted to utilize MGI’s automation and sequencing platform to power our CMTA solution.

MGI Tech Co., Ltd. (referred to as MGI) is committed to building core tools and technology to lead life science through intelligent innovation. With a focus on R&D, production and sales of DNA sequencing instruments, reagents, and related products, MGI provides real-time, panoramic, and full-life-cycle equipment and systems for precision medicine, precision healthcare and other relevant areas. MGI is a leading producer of clinical high-throughput gene sequencers, and its multi-omics platforms include genetic sequencing, medical imaging, and laboratory automation.

Sample to clinical report accredited workflow

Together we provide comprehensive end-to-end solutions for cancer diagnostics

Reliable laboratory automation to process the most precious cancer samples on the SP960 bundled with the powerful DNBSEQ technology of the IVD-CE G400 from MGI to enable data analysis and reporting through our CMTA.

In one single report, the CTMA delivers clinically-relevant interpreted information including:

  • Gene mutations & Tumor mutational burden (TMB) Chromosome number alterations (CNVs)
  • Loss of heterozygosity (LOH) regions
  • Gene amplifications and deletions with matched expression levels Gene fusions
  • Oncogenic transcript isoforms
  • Tumor microenvironment
  • Immune cells composition
  • Tumor subtype classification
  • Prognostic signatures of drug resistance